BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Dupixent Discussions - ECPv6.15.19//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dupixent Discussions
X-ORIGINAL-URL:https://www.dupixentdiscussions.com
X-WR-CALDESC:Events for Dupixent Discussions
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20240310T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20241103T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20260308T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20261101T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Chicago
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20240310T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20241103T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20250309T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20251102T070000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0600
TZOFFSETTO:-0500
TZNAME:CDT
DTSTART:20260308T080000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0500
TZOFFSETTO:-0600
TZNAME:CST
DTSTART:20261101T070000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251113T121500
DTEND;TZID=America/Los_Angeles:20251113T131500
DTSTAMP:20260408T142958
CREATED:20250829T203319Z
LAST-MODIFIED:20250926T005521Z
UID:10000740-1763036100-1763039700@www.dupixentdiscussions.com
SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Raffi Tachdjian\, MD
DESCRIPTION:Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=97597438455″]
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-raffi-tachdjian-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Chronic Spontaneous Urticaria (CSU)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Raffi-Tachdjian-1-e1705692089736-CmAgJG.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251112T121500
DTEND;TZID=America/Los_Angeles:20251112T131500
DTSTAMP:20260408T142958
CREATED:20250829T203329Z
LAST-MODIFIED:20250926T004311Z
UID:10000746-1762949700-1762953300@www.dupixentdiscussions.com
SUMMARY:Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age  by Brittany Craiglow\, MD
DESCRIPTION:Join us for a program discussing a real-world case of a pediatric patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation. [gravityform id=”1″ field_values=”zoomid=98410015485″]
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-joe-gorelick-np/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2023/05/Brittany-Craiglow-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251112T121500
DTEND;TZID=America/New_York:20251112T131500
DTSTAMP:20260408T142958
CREATED:20250829T203328Z
LAST-MODIFIED:20250924T200016Z
UID:10000745-1762949700-1762953300@www.dupixentdiscussions.com
SUMMARY:DUPIXENT@(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Sandri Johnson\, NP
DESCRIPTION:Join us for a virtual discussion with an expert speaker and an adult patient with prurigo nodularis (PN) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=99632311706″]
URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-patient-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-sandri-johnson-np/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Sandri-Johnson-NP-1jMtM8.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251110T121500
DTEND;TZID=America/Los_Angeles:20251110T131500
DTSTAMP:20260408T142958
CREATED:20250829T203328Z
LAST-MODIFIED:20250919T211733Z
UID:10000744-1762776900-1762780500@www.dupixentdiscussions.com
SUMMARY:DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Lakshi Aldredge\, NP
DESCRIPTION:Join us for a virtual discussion with an expert speaker and an adult patient with atopic dermatitis (AD) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=97111662107″]
URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-patient-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-lakshi-aldredge-np/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Lakshi-Aldredge-NP-MJutVB.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251110T121500
DTEND;TZID=America/New_York:20251110T131500
DTSTAMP:20260408T142958
CREATED:20250829T203328Z
LAST-MODIFIED:20250919T211724Z
UID:10000743-1762776900-1762780500@www.dupixentdiscussions.com
SUMMARY:Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age by Leigh Ann Pansch\, NP
DESCRIPTION:Learn more about the diagnosis and assessment of chronic spontaneous urticaria (CSU)\, including its clinical manifestations\, diagnostic evaluation\, assessment scales\, and a treatment option for appropriate CSU patients 12+ years of age[gravityform id=”1″ field_values=”zoomid=91482439268″]
URL:https://www.dupixentdiscussions.com/event/diagnosing-and-assessing-chronic-spontaneous-urticaria-csu-and-a-treatment-option-for-appropriate-csu-patients-12-years-of-age-by-leigh-ann-pansch-np/
LOCATION:Virtual (Zoom)
CATEGORIES:Chronic Spontaneous Urticaria (CSU)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Leigh-Ann-Pansch-NP-ebg15G.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20251106T121500
DTEND;TZID=America/Denver:20251106T131500
DTSTAMP:20260408T142958
CREATED:20250829T203319Z
LAST-MODIFIED:20250919T211716Z
UID:10000742-1762431300-1762434900@www.dupixentdiscussions.com
SUMMARY:Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP) by Daniel Butler\, MD
DESCRIPTION:Learn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations\, key\nlaboratory investigations for diagnostic evaluation\, consensus-based recommendations and a treatment option for appropriate BP patients[gravityform id=”1″ field_values=”zoomid=98116325780″]
URL:https://www.dupixentdiscussions.com/event/pearls-and-common-challenges-for-the-diagnosis-of-bullous-pemphigoid-bp-by-daniel-butler-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Bullous Pemphigoid (BP)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Daniel-Butler-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251106T121500
DTEND;TZID=America/New_York:20251106T131500
DTSTAMP:20260408T142958
CREATED:20250829T203319Z
LAST-MODIFIED:20251105T012941Z
UID:10000741-1762431300-1762434900@www.dupixentdiscussions.com
SUMMARY:Clinical Case Discussion: An Adolescent Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age  by Amy Spizuoco\, DO
DESCRIPTION:Join us for a program discussing a real-world case of an adolescent patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=91675843349″]
URL:https://www.dupixentdiscussions.com/event/clinical-case-discussion-an-adolescent-patient-with-uncontrolled-moderate-to-severe-atopic-dermatitis-and-a-treatment-option-for-appropriate-patients-6-months-of-age-by-michael-cameron-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2023/05/Amy-Spizuoco-DO.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20251104T121500
DTEND;TZID=America/Denver:20251104T131500
DTSTAMP:20260408T142958
CREATED:20250829T203318Z
LAST-MODIFIED:20250919T211655Z
UID:10000738-1762258500-1762262100@www.dupixentdiscussions.com
SUMMARY:Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age by Autumn Burnette\, MD
DESCRIPTION:Join us for a program discussing a real-world case of a pediatric patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=99103141305″]
URL:https://www.dupixentdiscussions.com/event/clinical-case-discussion-a-pediatric-patient-with-uncontrolled-moderate-to-severe-atopic-dermatitis-and-a-treatment-option-for-appropriate-patients-6-months-of-age-by-autumn-burnette-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Autumn-Burnette-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20251103T121500
DTEND;TZID=America/Chicago:20251103T131500
DTSTAMP:20260408T142958
CREATED:20250829T203315Z
LAST-MODIFIED:20250924T195938Z
UID:10000737-1762172100-1762175700@www.dupixentdiscussions.com
SUMMARY:DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Omar Noor\, MD
DESCRIPTION:Join us for a virtual discussion with an expert speaker and an adult patient with prurigo nodularis (PN) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=95080527083″]
URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-patient-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-omar-noor-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Omar-Noor-MD-is4bst.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251103T121500
DTEND;TZID=America/New_York:20251103T124500
DTSTAMP:20260408T142958
CREATED:20250829T203315Z
LAST-MODIFIED:20250926T005501Z
UID:10000736-1762172100-1762173900@www.dupixentdiscussions.com
SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Karan Lal\, DO
DESCRIPTION:This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. \nRegister \n 
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-karan-lal-do/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Karan-Lal-DO.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251030T121500
DTEND;TZID=America/New_York:20251030T131500
DTSTAMP:20260408T142958
CREATED:20250829T203315Z
LAST-MODIFIED:20250926T005436Z
UID:10000735-1761826500-1761830100@www.dupixentdiscussions.com
SUMMARY:A Treatment Option for Appropriate Patients with Certain  Skin Diseases Driven in Part by Type 2 Inflammation by Marc Serota\, MD
DESCRIPTION:Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=93096101600″]
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-marc-serota-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Multi-Indication (AD/PN/CSU/BP)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Marc-Serota-e1705692168783-K9yvcY.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251029T121500
DTEND;TZID=America/Los_Angeles:20251029T131500
DTSTAMP:20260408T142958
CREATED:20250829T203314Z
LAST-MODIFIED:20250919T211551Z
UID:10000734-1761740100-1761743700@www.dupixentdiscussions.com
SUMMARY:Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Ben Ehst\, MD
DESCRIPTION:Learn more about itch in patients with atopic dermatitis (AD)\, prurigo nodularis (PN)\, and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=97139430213″]
URL:https://www.dupixentdiscussions.com/event/beneath-the-itch-the-role-of-type-2-inflammation-and-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-ben-ehst-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Multi-Indication (AD/PN/CSU/BP)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2023/05/Benjamin-Ehst-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251029T121500
DTEND;TZID=America/New_York:20251029T124500
DTSTAMP:20260408T142958
CREATED:20250829T203314Z
LAST-MODIFIED:20250926T005413Z
UID:10000733-1761740100-1761741900@www.dupixentdiscussions.com
SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Douglas DiRuggiero\, PA-C
DESCRIPTION:This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. \nRegister \n 
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-douglas-diruggiero-pa-c/
LOCATION:Virtual (Zoom)
CATEGORIES:Bullous Pemphigoid (BP)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/05/Douglas-DiRuggiero-PA-C.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251028T121500
DTEND;TZID=America/New_York:20251028T131500
DTSTAMP:20260408T142958
CREATED:20250829T203312Z
LAST-MODIFIED:20250919T211533Z
UID:10000732-1761653700-1761657300@www.dupixentdiscussions.com
SUMMARY:DUPIXENT®(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Roopen Patel\, MD
DESCRIPTION:Join us for a virtual discussion with an expert speaker and an adult patient with atopic dermatitis (AD) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=94221308275″]
URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-patient-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-roopen-patel-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Roopen-Patel-MD-vKymuR.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20251027T121500
DTEND;TZID=America/Chicago:20251027T131500
DTSTAMP:20260408T142958
CREATED:20250829T203312Z
LAST-MODIFIED:20260206T162535Z
UID:10000731-1761567300-1761570900@www.dupixentdiscussions.com
SUMMARY:Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP) by Timothy Patton\, DO
DESCRIPTION:Learn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations\, key\nlaboratory investigations for diagnostic evaluation\, consensus-based recommendations and a treatment option for appropriate BP patients
URL:https://www.dupixentdiscussions.com/event/pearls-and-common-challenges-for-the-diagnosis-of-bullous-pemphigoid-bp-by-timothy-patton-dp/
LOCATION:Virtual (Zoom)
CATEGORIES:Bullous Pemphigoid (BP)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Timothy-Patton-DO.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20251023T121500
DTEND;TZID=America/Chicago:20251023T131500
DTSTAMP:20260408T142958
CREATED:20250829T203311Z
LAST-MODIFIED:20250919T211509Z
UID:10000730-1761221700-1761225300@www.dupixentdiscussions.com
SUMMARY:Clinical Case Discussion: An Adult Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age  by Marshall Shuler\, MD
DESCRIPTION:Join us for a program discussing a real-world case of an adult patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=92580673185″]
URL:https://www.dupixentdiscussions.com/event/clinical-case-discussion-an-adult-patient-with-uncontrolled-moderate-to-severe-atopic-dermatitis-and-a-treatment-option-for-appropriate-patients-6-months-of-age-by-marshall-shuler-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Marshall-Shuler-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251022T121500
DTEND;TZID=America/Los_Angeles:20251022T131500
DTSTAMP:20260408T142958
CREATED:20250829T203311Z
LAST-MODIFIED:20250924T195827Z
UID:10000729-1761135300-1761138900@www.dupixentdiscussions.com
SUMMARY:DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Zakiya Rice\, MD
DESCRIPTION:Join us for a virtual discussion with an expert speaker and an adult patient with prurigo nodularis (PN) to Learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=94142696433″]
URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-patient-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-zakiya-rice-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Zakiya-Rice-MD-9UKcCE.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251022T121500
DTEND;TZID=America/New_York:20251022T124500
DTSTAMP:20260408T142958
CREATED:20250829T203318Z
LAST-MODIFIED:20250926T005354Z
UID:10000739-1761135300-1761137100@www.dupixentdiscussions.com
SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Eileen Cheever\, PA-C
DESCRIPTION:This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. \nRegister \n 
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-eileen-cheever-pa-c/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Eileen-Cheever-PA-C.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20251021T121500
DTEND;TZID=America/Chicago:20251021T131500
DTSTAMP:20260408T142958
CREATED:20250829T203310Z
LAST-MODIFIED:20250926T004207Z
UID:10000728-1761048900-1761052500@www.dupixentdiscussions.com
SUMMARY:The Shades of Atopic Dermatitis in Skin of Color and a Treatment Option for Appropriate Patients with Type 2 Inflammation by Fred Ghali\, MD
DESCRIPTION:Learn more about the distinctive ways that atopic dermatitis (AD) may present in patients with skin of color and a treatment option that may help appropriate patients with Type 2 inflammation. [gravityform id=”1″ field_values=”zoomid=98568417023″]
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-fred-ghali-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Fred-Ghali-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251021T121500
DTEND;TZID=America/Los_Angeles:20251021T131500
DTSTAMP:20260408T142958
CREATED:20250829T203309Z
LAST-MODIFIED:20250919T211401Z
UID:10000727-1761048900-1761052500@www.dupixentdiscussions.com
SUMMARY:The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients. by Linda Stein Gold\, MD
DESCRIPTION:Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD)\, prurigo nodularis (PN)\, and chronic spontaneous urticaria (CSU); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=97180233477″]
URL:https://www.dupixentdiscussions.com/event/the-many-faces-of-type-2-inflammation-unraveling-its-role-across-dermatologic-conditions-and-a-treatment-option-for-appropriate-patients-by-linda-stein-gold-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Multi-Indication (AD/PN/CSU/BP)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Linda-Stein-Gold-MD-rJXGOQ.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20251020T121500
DTEND;TZID=America/Chicago:20251020T131500
DTSTAMP:20260408T142958
CREATED:20250829T203309Z
LAST-MODIFIED:20250919T211348Z
UID:10000726-1760962500-1760966100@www.dupixentdiscussions.com
SUMMARY:DUPIXENT® (dupilumab) Pediatric Caregiver Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Dareen Siri\, MD
DESCRIPTION:Join us for a virtual discussion with an expert speaker and a caregiver of a pediatric patient with atopic dermatitis (AD) to learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=91691990582″]
URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-patient-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-dareen-siri-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/04/Dareen-Siri-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20251016T121500
DTEND;TZID=America/Chicago:20251016T131500
DTSTAMP:20260408T142958
CREATED:20250829T203308Z
LAST-MODIFIED:20250926T004057Z
UID:10000725-1760616900-1760620500@www.dupixentdiscussions.com
SUMMARY:Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age   by Dareen Siri\, MD
DESCRIPTION:Join us for a program discussing a real-world case of a pediatric patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation. [gravityform id=”1″ field_values=”zoomid=93788306547″]
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-dareen-siri-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/04/Dareen-Siri-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251016T121500
DTEND;TZID=America/New_York:20251016T131500
DTSTAMP:20260408T142958
CREATED:20250829T203308Z
LAST-MODIFIED:20250919T211325Z
UID:10000724-1760616900-1760620500@www.dupixentdiscussions.com
SUMMARY:Clinical Case Discussion: An Adult Patient with Prurigo Nodularis and a Treatment Option for Appropriate Patients 18+ Years of Age by Michael Payette\, MD
DESCRIPTION:Join us for a program discussing a real-world case of an adult patient with prurigo nodularis (PN) and a treatment option that may help appropriate patients.[gravityform id=”1″ field_values=”zoomid=96909945859″]
URL:https://www.dupixentdiscussions.com/event/clinical-case-discussion-a-62-year-old-female-with-itchy-skin-lesions-could-it-be-pn-by-michael-payette-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Michael-Payette-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251015T121500
DTEND;TZID=America/Los_Angeles:20251015T131500
DTSTAMP:20260408T142958
CREATED:20250829T203308Z
LAST-MODIFIED:20250919T211311Z
UID:10000723-1760530500-1760534100@www.dupixentdiscussions.com
SUMMARY:Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)  by Matthew Lewis\, MD
DESCRIPTION:Learn more about the diagnosis and assessment of bullous pemphigoid (BP) including clinical manifestations\, key\nlaboratory investigations for diagnostic evaluation\, consensus-based recommendations and a treatment option for appropriate BP patients[gravityform id=”1″ field_values=”zoomid=91473816744″]
URL:https://www.dupixentdiscussions.com/event/pearls-and-common-challenges-for-the-diagnosis-of-bullous-pemphigoid-bp-by-matthew-lewis-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Bullous Pemphigoid (BP)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Matthew-Lewis-MD.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20251015T121500
DTEND;TZID=America/Chicago:20251015T131500
DTSTAMP:20260408T142958
CREATED:20250829T203302Z
LAST-MODIFIED:20250919T211259Z
UID:10000722-1760530500-1760534100@www.dupixentdiscussions.com
SUMMARY:Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Ty Hanson\, DO
DESCRIPTION:Learn more about itch in patients with atopic dermatitis (AD)\, prurigo nodularis (PN)\, and chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=99633835139″]
URL:https://www.dupixentdiscussions.com/event/beneath-the-itch-the-role-of-type-2-inflammation-and-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-ty-hanson-do/
LOCATION:Virtual (Zoom)
CATEGORIES:Multi-Indication (AD/PN/CSU/BP)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Ty-Hanson-DO.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251014T121500
DTEND;TZID=America/New_York:20251014T131500
DTSTAMP:20260408T142958
CREATED:20250829T203302Z
LAST-MODIFIED:20250919T211243Z
UID:10000721-1760444100-1760447700@www.dupixentdiscussions.com
SUMMARY:DUPIXENT@ (dupilumab) Pediatric Caregiver Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Lisa Swanson\, MD
DESCRIPTION:Join us for a virtual discussion with an expert speaker and a caregiver of a pediatric patient with atopic dermatitis (AD) to learn more about a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=95867877266″]
URL:https://www.dupixentdiscussions.com/event/dupixent%c2%a8-dupilumab-pediatric-caregiver-story-followed-by-a-treatment-option-for-appropriate-patients-with-certain-skin-diseases-driven-in-part-by-type-2-inflammation-by-lisa-swanson-md/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Lisa-Swanson-MD-uTtlDn.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Chicago:20251009T121500
DTEND;TZID=America/Chicago:20251009T131500
DTSTAMP:20260408T142958
CREATED:20250829T203302Z
LAST-MODIFIED:20250920T005122Z
UID:10000720-1760012100-1760015700@www.dupixentdiscussions.com
SUMMARY:Exploring the Pathophysiology of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age by Cynthia Trickett\, PA-C
DESCRIPTION:Learn more about the evolving understanding of the pathophysiology of chronic spontaneous urticaria (CSU) and a treatment option that may help appropriate CSU patients 12+ years of age. [gravityform id=”1″ field_values=”zoomid=97704866735″]
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-cynthia-trickett-pa-c/
LOCATION:Virtual (Zoom)
CATEGORIES:Chronic Spontaneous Urticaria (CSU)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Cynthia-Trickett-PA-C.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251008T121500
DTEND;TZID=America/New_York:20251008T124500
DTSTAMP:20260408T142958
CREATED:20250829T203301Z
LAST-MODIFIED:20250926T005312Z
UID:10000719-1759925700-1759927500@www.dupixentdiscussions.com
SUMMARY:A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Gina Mangin\, PA-C
DESCRIPTION:This program is being held in partnership with SDPA. Please visit the link below to be taken to the registration page for this program. \nRegister \n 
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-gina-mangin-pa-c/
LOCATION:Virtual (Zoom)
CATEGORIES:Prurigo Nodularis (PN)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/06/Gina-Mangin-PA-C.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20251007T121500
DTEND;TZID=America/Los_Angeles:20251007T131500
DTSTAMP:20260408T142958
CREATED:20250829T203301Z
LAST-MODIFIED:20250919T211133Z
UID:10000718-1759839300-1759842900@www.dupixentdiscussions.com
SUMMARY:The Many Faces of Type 2 Inflammation: Unraveling Its Role Across Dermatologic Conditions and a Treatment Option for Appropriate Patients  by Justin Love\, PA-C
DESCRIPTION:Learn more about how Type 2 inflammation contributes to the clinical manifestations of atopic dermatitis (AD)\, prurigo nodularis (PN)\, and chronic spontaneous urticaria (CSU); which cytokines play key roles in driving this activity; and a treatment option that may help appropriate patients with certain skin diseases driven in part by Type 2 inflammation[gravityform id=”1″ field_values=”zoomid=97505469030″]
URL:https://www.dupixentdiscussions.com/event/the-many-faces-of-type-2-inflammation-unraveling-its-role-across-dermatologic-conditions-and-a-treatment-option-for-appropriate-patients-by-justin-love-pa-c/
LOCATION:Virtual (Zoom)
CATEGORIES:Multi-Indication (AD/PN/CSU/BP)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Justin-Love-PA-C.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251006T121500
DTEND;TZID=America/New_York:20251006T131500
DTSTAMP:20260408T142958
CREATED:20250829T203258Z
LAST-MODIFIED:20250920T005047Z
UID:10000717-1759752900-1759756500@www.dupixentdiscussions.com
SUMMARY:Clinical Case Discussion: An Adult Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age by Andrew Baker\, PA-C
DESCRIPTION:Join us for a program discussing a real-world case of an adult patient with moderate-to-severe atopic dermatitis (AD) and a treatment option that may help appropriate patients with Type 2 inflammation. \n[gravityform id=”1″ field_values=”zoomid=96374288045″]
URL:https://www.dupixentdiscussions.com/event/a-treatment-option-for-appropriate-patients-with-skin-diseases-driven-in-part-by-type-2-inflammation-by-andrew-baker-pa-c/
LOCATION:Virtual (Zoom)
CATEGORIES:Atopic Dermatitis (AD)
ATTACH;FMTTYPE=image/png:https://www.dupixentdiscussions.com/wp-content/uploads/2025/08/Andrew-Baker-PA-C.png
END:VEVENT
END:VCALENDAR